SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oncothyreon
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: geneguru who wrote (2150)5/21/2013 9:16:40 AM
From: bmaz0012 Recommendations  Read Replies (1) of 2344
 
Steve,

Is it realistic to expect the FDA to approve BLP25 based on the recently released statistics associated with the cCRT subset? Isn't it much more likely that another PIII trial will need to be conducted and that the cost and time associated with that trial will make ONTY quite a risky investment at this point? Do you have a reasonably realistic scenario or two that you'd be willing to share? I don't have enough experience in this space to hypothesize about what is/isn't possible with regard to the FDA hurdle(s).

Thanks,
-Maz
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News